COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: "what the bleep do we know?"

The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a "Pandemic" and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative stra...

Full description

Saved in:
Bibliographic Details
Published in:The Egyptian Journal of Neurology, Psychiatry and Neurosurgery Psychiatry and Neurosurgery, 2020-05, Vol.56 (1), p.44-44
Main Authors: Mansoor, Salman, Kelly, Siobhan, Murphy, Kevin, Waters, Aine, Siddiqui, Nauman Saleem
Format: Article
Language:English
Subjects:
Coronavirus
Coronaviruses
COVID-19
Disease modifying therapies
Multiple sclerosis
Pandemics
Review
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The novel coronavirus which emerged in Wuhan province of China has taken world by surprise. Since been diagnosed in December 2019, it has been termed a "Pandemic" and there is a growing concern in physicians across the globe. As new evidence is emerging, there are various preventative strategies which are being deployed. Multiple sclerosis patients who are on disease modifying therapies (DMTs) might be at a higher risk of acquiring or a poorer outcome due to their immune status. This review looks at the available evidence in managing this global crisis.
ISSN:1110-1083
1687-8329
DOI:10.1186/s41983-020-00177-0